Peptide Inhibitors for Viral Infections and as Anti-inflammatory Agents


IFN-gamma and IL-10 are cytokine signaling molecules that play fundamental roles in inflammation, cancer growth and autoimmune diseases.  Unfortunately, there are no specific inhibitors of IFN-gamma or IL-10 on the market to date.

NCI investigators at the Cancer and Inflammation Program have synthesized short peptides that selectively interfere with dimerization of the cytokines and their binding to the corresponding receptor. The peptides include metabolically stable lipopeptides mimicking conserved regions of IL-10 and IFN-gamma receptors that interfere with STAT3 and STAT1 phosphorylation and subsequent signaling. The lipopeptides strongly inhibit STAT3 and STAT1-dependent growth of cancer cells. These compounds are promising drug candidates for the treatment of cancer and many infectious and inflammatory diseases. 



Potential Commercial Applications: Competitive Advantages:

- Cancer, viral infections and anti-inflammatory treatments
- Dermatological treatment for psoriasis

 

- Rationally designed and synthesized to be potent, metabolically stable, and more therapeutic
- Highly selective IL-10 and IFN-gamma inhibitors



Development Stage:
Pre-clinical (in vivo)

Inventors:

Nadya Tarasova (NCI)  ➽ more inventions...

Giorgio Trinchieri (NCI)  ➽ more inventions...

Howard Young (NCI)  ➽ more inventions...


Intellectual Property:
US Application No. 13/697,259
EP Application No. Application No. 11720697.9

Publications:
Timofeeva OA, et al. PMID: 18154267

Collaboration Opportunity:

Licensing and research collaboration


Licensing Contact:
John Hewes, Ph.D.
Email: John.Hewes@nih.gov
Phone: 240-276-5515

OTT Reference No: E-167-2010
Updated: Aug 31, 2016